Tuesday 13 October 2026
Export ASMB’s income statement to Excel — free account
Assembly Biosciences, Inc.
ASMB Healthcare Biotechnology
Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024. In the quarter to June 2026, revenue grew 38.9%, EPS grew 85.0% and free cash flow grew 7.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
20.63
2.14
−9.40%
Follow ASMB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | — | — | — | 3 | 3 | 3 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
1.06 | (9.38) | (8.44) | — | (3.29) | 0.91 | 2.98 | 3.43 | 6.31 | — |
P/S ratio |
5.27 | 3.32 | 0.56 | — | 1.24 | 2.71 | 33.64 | 34.83 | 91.05 | — |
Altman Z″-Score (non-manufacturers) |
(1.34) | (21.02) | (16.91) | — | (2.68) | 3.24 | 3.04 | 2.37 | (0.54) | — |
P/FCF ratio |
0.00 | 0.00 | 2.03 | — | 0.00 | 0.00 | 0.00 | 0.00 | 965.84 | — |
Beneish M-Score |
— | — | — | — | (3.55) | (0.55) | (2.34) | (2.89) | — | — |
P/Operating CF |
26.78 | (232.82) | 0.62 | — | (5.21) | (8.48) | (26.16) | (30.82) | (84.05) | — |
P/B ratio |
1.84 | 2.84 | 1.11 | — | 0.60 | 0.89 | 1.97 | 2.45 | 7.26 | — |
Price to Tangible BV |
2.31 | 0.00 | 0.00 | — | 0.79 | 1.08 | 2.32 | 3.05 | 11.49 | — |
EV/Sales |
1.84 | (0.61) | (1.04) | — | (0.56) | (0.03) | 16.48 | 20.10 | 77.75 | — |
EV/EBITDA |
0.00 | 0.35 | 1.16 | — | 0.51 | 0.03 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(3.24) | 0.34 | (3.72) | — | 0.49 | 0.03 | (3.13) | (4.58) | 376.99 | — |
EV/FCF |
(3.24) | 0.34 | (3.76) | — | 0.48 | 0.03 | (3.07) | (4.56) | 824.76 | — |
Quick Ratio |
5.11 | 2.34 | 3.32 | 5.68 | 9.14 | 8.91 | 11.35 | 11.94 | 9.06 | 7.44 |
Current Ratio |
5.22 | 2.42 | 3.41 | 5.95 | 9.59 | 9.19 | 11.57 | 12.05 | 9.13 | 7.52 |
Net Debt/EBITDA |
17.31 | 2.29 | 1.98 | 0.98 | 1.63 | 3.38 | 2.64 | 2.36 | 2.31 | 1.17 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.38 | 0.22 | 0.06 | 0.00 | 0.03 | 0.25 | 0.05 | 0.07 | 0.07 | 0.00 |
Operating CF/Net income |
6.71 | 1.27 | (0.37) | 0.91 | 0.72 | 1.01 | 0.86 | 0.72 | (0.04) | 0.79 |
Capex/Depreciation |
0.03 | 0.01 | 0.20 | (0.16) | (0.05) | (0.69) | 1.25 | (0.82) | (3.95) | (1.84) |
| (5.10%) | (107.92%) | (98.95%) | (74.00%) | (63.42%) | (24.19%) | (40.36%) | (56.06%) | (44.36%) | (44.57%) | |
| (3.25%) | (31.39%) | (51.32%) | (63.58%) | (54.75%) | (19.95%) | (32.12%) | (41.50%) | (32.02%) | (38.18%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (371.85%) | (167.54%) | 0.00% | 0.00% | 0.00% | (105.14%) |
Return on Tangible Assets |
(2.97%) | (59.10%) | (64.49%) | (114.34%) | (93.24%) | (30.82%) | (37.53%) | (44.36%) | (38.75%) | (94.84%) |
Average Days of Receivables |
4.92 | 0.00 | 2.19 | 0.00 | 19.61 | 5.68 | 77.15 | 59.91 | 92.03 | — |
Research and Development Expense of Revenue |
89.64% | 196.12% | 682.67% | 0.00% | 1,095.68% | 135.04% | 537.22% | 491.36% | 490.35% | 0.00% |
Selling, General and Administrative Expense of Revenue |
27.12% | 63.14% | 319.82% | 0.00% | 460.19% | 46.85% | 206.22% | 235.06% | 188.72% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.15 | 0.12 | 0.16 | 0.25 | 0.42 |
Share Based Compensation of Revenue |
6.47% | 10.94% | 71.46% | 0.00% | 83.74% | 27.63% | 128.79% | 192.41% | 95.37% | 0.00% |
Graham Net Nets |
0.53 | 0.31 | 0.83 | — | 1.31 | 0.85 | 0.40 | 0.32 | 0.08 | — |
Graham Number |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(2.18%) | (42.59%) | (133.26%) | — | (129.67%) | (28.94%) | (18.19%) | (17.69%) | (5.32%) | — |
Free Cash Flow Yield |
(10.79%) | (53.97%) | 49.38% | — | (94.87%) | (29.60%) | (15.94%) | (12.67%) | 0.10% | — |
Revenue per Share |
6.45 | 4.75 | 1.57 | 0.00 | 1.73 | 26.81 | 7.30 | 7.79 | 6.10 | 0.00 |
Operating CF per Share |
(3.67) | (8.51) | 4.97 | (20.94) | (25.91) | (21.33) | (38.43) | (34.20) | 1.26 | (24.31) |
Capex per Share |
(0.01) | 0.00 | (0.05) | (0.03) | (0.62) | (0.16) | (0.71) | (0.18) | (0.58) | (0.10) |
Free Cash Flow per Share |
(3.67) | (8.52) | 4.92 | (20.96) | (26.53) | (21.49) | (39.14) | (34.38) | 0.67 | (24.41) |
Cash per Share |
22.13 | 18.66 | 28.46 | 22.71 | 40.67 | 73.33 | 125.28 | 114.82 | 81.12 | 36.91 |
Shareholders Equity per Share |
18.44 | 5.56 | 8.98 | 20.49 | 46.86 | 81.52 | 124.90 | 110.91 | 76.50 | 55.67 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
18.44 | 5.56 | 8.98 | 20.49 | 46.86 | 81.52 | 124.90 | 110.91 | 76.50 | 55.67 |
Free Cash Flow |
(41.16) | (51.14) | 22.51 | (84.56) | (95.63) | (63.43) | (85.62) | (65.30) | 1.00 | (35.03) |
Working Capital |
205.77 | 67.70 | 94.56 | 80.67 | 138.13 | 200.06 | 258.34 | 204.03 | 109.63 | 46.45 |
Capital Expenditures |
(0.07) | (0.03) | (0.23) | (0.10) | (2.24) | (0.47) | (1.55) | (0.34) | (0.86) | (0.15) |
Net Current Asset Value |
203.71 | 29.69 | 38.06 | 77.84 | 132.07 | 181.82 | 216.09 | 165.11 | 66.94 | 35.33 |
EV/EBIT |
0.00 | 0.38 | 1.31 | — | 0.35 | 0.03 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.03 | 0.00 | 0.36 | 0.01 | 0.10 | 0.02 | 0.10 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(10.03) | (12.43) | (2.95) | 0.88 | 37.48 | 0.42 | (0.68) | 0.74 | 0.25 | 0.37 |
Cash ROIC |
(9.05%) | (35.17%) | 13.14% | (48.52%) | (30.31%) | (13.88%) | (15.65%) | (15.23%) | 0.43% | (26.37%) |
Accounts Receivable Turnover |
142.19 | 0.00 | 14.51 | 0.00 | 7.99 | 34.36 | 5.50 | 6.29 | 3.84 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — | 0.00 |
Average Receivables |
0.51 | — | 0.49 | 0.64 | 0.78 | 2.30 | 2.90 | 2.35 | 2.35 | — |
Average Payables |
0.88 | 0.52 | 1.48 | 2.58 | 3.63 | 3.16 | 2.71 | 2.91 | 2.25 | 1.87 |
Average Assets |
188.38 | 128.00 | 119.31 | 146.43 | 237.16 | 311.58 | 303.98 | 218.67 | 133.71 | 115.93 |
Average Common Equity |
120.06 | 37.23 | 61.88 | 125.80 | 204.75 | 256.90 | 241.94 | 161.89 | 96.50 | 99.31 |
Columns are period end dates